Feb. 2022

Company Introduction

onconic therapeutics

"Oncology + Iconic"

CEO	John Kim, Ph.D.
Foundation date	2020. May. 7th. Spin-off from Jeil Pharma
Main pipeline	- JPI-547 (Oncology) - JP-1366 (Gastric disease)
Goals	Approval at least 2 global breakthrough therapies in 3 years
Location	Seoul, Republic of Korea

Pipelines



*In collaboration with Jeil Pharma, Korean domestic and foreign research institutes

2nd generation PARP inhibitor

for "PARPi resistant cancers"



PARP: poly ADP-ribose polymerase

Introduction

- Poly (ADP-ribose) polymerase inhibitor (PARPi)
  - Synthetic lethality by inhibiting DNA repair pathways
- Tankyrase (TNKS) inhibitor
  - Suppression of Wnt/β-catenin signaling and prevention of tumor growth
- Limitation of marketed PARP inhibitors
  - Development of resistance to PARPi
- JPI-547
  - Potent inhibitor of both PARPs and TNKS
  - Potential to overcome PARPi resistance as a dual PARP/TNKS inhibitor

Product summary

- Broad spectrum of anti-cancer potential on several solid tumors in vitro and in vivo (Mono/combination therapy)
  - Ovarian, NSCLC, breast, pancreatic, gastric, prostate, colorectal cancer

- JPI-547 monotherapy showed efficacy (ASCO 2021)
  - In patients with mBRCA1/2 or HRD (ORR 28 %, DCR 67 %)
  - In olaparib resistant patients

- No additional safety signals identified as PARP/TNKS dual inhibitor

NSCLC: non small cell lung cancer, ORR: overall response rate, DCR: disease control rate

Clinical trial status

Phase	Status
Phase 1	Completed
Phase 1b	Pancreatic cancer, start in Q1 2022
Phase 2	Ovarian cancer in previously PARPi treated patients, start in Q1 2022

Why JPI-547?

- Comparable safety profile to marketed PARPi
- Potential efficacy on various BRCA/non-BRCA mutated solid tumors and in PARPi resistant patients

IP Status

- IP of compound, method for preparing same, and pharmaceutical composition comprising same
  - Expiration date: 2036. 06. 03 (+ PTE 5yrs)
  - Patented in about 20 countries (US, EU, Japan and China)
  - All IP rights were transferred from Jeil Pharma to Onconic therapeutics in 2020 (Except Korea)

- IP of Method for determining sensitivity to simultaneous inhibitor against PARP/tankyrase (Companion diagnostics for Colorectal cancer)
  - Expiration date: 2035. 07.06
  - Patented in the US and under review in EU and China

Best-in-class P-CAB

JP-1366, Potassium-Competitive Acid Blocker

Background

- Potassium-competitive Acid Blocker (P-CAB)
- Reversibly blocks the H+/K+-ATPase
- Expected to fulfill the unmet needs of current therapeutic modalities for GERD
- Global GERD Market size is expected to reach USD 6.14 Billion by 2027

Advantages over other PPIs/P-CABs

Rapid Onset

- Rapid inhibition of acid secretion

Prolonged effect

- Sustained inhibitory effects

Higher Drug Compliance

- No food effect
- Once daily dosing

Clinical Summary

- Fast acid suppression (gastric pH > 4) than other P-CABs
- In phase 2 trial,
  - Healing rate **non-inferior** to esomeprazole
  - Comparable safety profile
  - Faster symptom relief
- Clinical trial status
  - Phase 2: completed
  - Phase 3: start in 4Q 2021

Compound	Time to pH 4
JP-1366	~ 1h
P-CAB1	~ 2h
P-CAB2	~ 1h
P-CAB3	~ 4h

Why JP-1366?

- Best-in-class P-CAB with **rapid onset** and **prolonged effect**



IP Status

- IP of compound, method for preparing same, and pharmaceutical composition comprising same
  - Expiration date
    - Korea: 2036. 07. 05 (+ PTE 5yrs)
    - Global: 2037.07. 04 (+ PTE 5yrs)
  - Patented in about 44 countries (US, EU(22 countries), Japan and China, etc.,)

Many thanks

for your time and consideration